Oppenheimer analyst Suraj Kalia raised the firm's price target on Pulse Biosciences to $30 from $22 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 revenues of $0.3M vs. its $0.3M estimate, following soft-tissue ablation platform launch in Q3 2025. Pulse received FDA approval to commence pivotal IDE study of nPulse Cardiac Catheter for paroxysmal-AF, to begin enrollment in next few months, completing Q4 2026. This follows feasibility study data, and while encouraging to say the least, results require confirmation in larger trials, Oppenheimer adds.
